Clinical Trial Update: Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting efficacy and safety of donafenib in advanced hepatocellular carcinoma across Phase 2 and Phase 3 (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: HCC | Phase 2, Phase 3 | Status: COMPLETED